Viatris Inc.
VTRSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeViatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America,. Valued at $21.01B, VTRS is a large-cap name in its sector. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Market Cap
$21.01B
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
6.78
EPS (TTM)
$-0.36
EPS (Fwd)
$2.70
ROE
-2.8%
ROA
2.7%
Cash
$1.51B
Total Debt
$13.62B
Free CF
$2.68B
52W Change
75.5%
Annual Financials
Cash vs Debt
Where VTRS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VTRS finished 14.05% above its 150-day moving average ($16.01) and 18.11% above its 200-day moving average ($15.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VTRS overbought or oversold?
At the October 20, 2026 close, VTRS's RSI(14) was 52.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.51B in cash, though total debt stands at $13.62B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $2.68B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -2.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $17.89B (2021) to $14.30B (2025), a 20% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing VTRS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.